Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Terpenoids and Cardiovascular Disease: Evidence Overview

Terpenoids, a large class of naturally occurring organic chemicals derived from terpenes, are found in many medicinal plants and have attracted scientific attention for their potential cardiovascular benefits. Several terpenoids—including artemisinin, ginkgolides (from Ginkgo biloba), and carotenoids—have been studied in relation to cardiovascular disease (CVD).

Experimental and some clinical studies suggest that certain terpenoids can exert anti-inflammatory, antioxidant, antiplatelet, and lipid-lowering effects, all of which are relevant to the prevention and management of CVD. For example, ginkgolides have been shown to inhibit platelet-activating factor, reducing the risk of thrombosis. Studies on carotenoids (such as beta-carotene and lycopene) indicate potential for reducing oxidative stress and improving endothelial function, although clinical outcomes remain mixed.

However, while preclinical (in vitro and animal) studies are promising, robust clinical evidence in humans remains limited. Meta-analyses and randomized controlled trials have not consistently demonstrated a significant benefit in reducing cardiovascular events. Thus, while terpenoids are the subject of scientific investigation and there is some mechanistic and early clinical support, the evidence base is not yet strong enough to warrant widespread use in cardiovascular disease management outside of research settings.

In summary, there is scientific basis for the investigation of terpenoids in cardiovascular disease, but current evidence is moderate and not definitive. More large-scale, high-quality clinical trials are needed to establish their efficacy and safety for this indication.

More about Terpenoids
More about Cardiovascular Disease

Other ingredients used for Cardiovascular Disease

Other health conditions supported by Terpenoids

Products containing Terpenoids